Your browser doesn't support javascript.
loading
Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
Decaudin, Didier; Frisch Dit Leitz, Estelle; Nemati, Fariba; Tarin, Malcy; Naguez, Adnan; Zerara, Mohamed; Marande, Benjamin; Vivet-Noguer, Raquel; Halilovic, Ensar; Fabre, Claire; Jochemsen, Aart; Roman-Roman, Sergio; Alsafadi, Samar.
Afiliação
  • Decaudin D; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France; Department of Medical Oncology, Institut Curie, Paris, France.
  • Frisch Dit Leitz E; Uveal Melanoma Translational Group, Department of Translational Research, Institut Curie, PSL Research University, Paris, France.
  • Nemati F; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France.
  • Tarin M; Uveal Melanoma Translational Group, Department of Translational Research, Institut Curie, PSL Research University, Paris, France.
  • Naguez A; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France.
  • Zerara M; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France.
  • Marande B; Uveal Melanoma Translational Group, Department of Translational Research, Institut Curie, PSL Research University, Paris, France.
  • Vivet-Noguer R; Uveal Melanoma Translational Group, Department of Translational Research, Institut Curie, PSL Research University, Paris, France.
  • Halilovic E; Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
  • Fabre C; Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
  • Jochemsen A; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.
  • Roman-Roman S; Uveal Melanoma Translational Group, Department of Translational Research, Institut Curie, PSL Research University, Paris, France.
  • Alsafadi S; Uveal Melanoma Translational Group, Department of Translational Research, Institut Curie, PSL Research University, Paris, France. Electronic address: samar.alsafadi@curie.fr.
Eur J Cancer ; 126: 93-103, 2020 02.
Article em En | MEDLINE | ID: mdl-31927215
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Uveais / Protocolos de Quimioterapia Combinada Antineoplásica / Avaliação Pré-Clínica de Medicamentos / Melanoma Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Uveais / Protocolos de Quimioterapia Combinada Antineoplásica / Avaliação Pré-Clínica de Medicamentos / Melanoma Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article